AU2012207301B2 - Apolipoprotein AIV as an antidiabetic peptide - Google Patents

Apolipoprotein AIV as an antidiabetic peptide Download PDF

Info

Publication number
AU2012207301B2
AU2012207301B2 AU2012207301A AU2012207301A AU2012207301B2 AU 2012207301 B2 AU2012207301 B2 AU 2012207301B2 AU 2012207301 A AU2012207301 A AU 2012207301A AU 2012207301 A AU2012207301 A AU 2012207301A AU 2012207301 B2 AU2012207301 B2 AU 2012207301B2
Authority
AU
Australia
Prior art keywords
apolipoprotein
apoa
subject
biologically active
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012207301A
Other languages
English (en)
Other versions
AU2012207301A8 (en
AU2012207301A1 (en
AU2012207301A2 (en
Inventor
Sean Davidson
Patrick Tso
Fei Wang
Stephen Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2012207301A1 publication Critical patent/AU2012207301A1/en
Publication of AU2012207301A8 publication Critical patent/AU2012207301A8/en
Publication of AU2012207301A2 publication Critical patent/AU2012207301A2/en
Application granted granted Critical
Publication of AU2012207301B2 publication Critical patent/AU2012207301B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012207301A 2011-01-19 2012-01-19 Apolipoprotein AIV as an antidiabetic peptide Ceased AU2012207301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434196P 2011-01-19 2011-01-19
US61/434,196 2011-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide

Publications (4)

Publication Number Publication Date
AU2012207301A1 AU2012207301A1 (en) 2013-08-01
AU2012207301A8 AU2012207301A8 (en) 2013-08-29
AU2012207301A2 AU2012207301A2 (en) 2015-03-26
AU2012207301B2 true AU2012207301B2 (en) 2016-05-19

Family

ID=45755499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012207301A Ceased AU2012207301B2 (en) 2011-01-19 2012-01-19 Apolipoprotein AIV as an antidiabetic peptide

Country Status (13)

Country Link
US (2) US9051394B2 (OSRAM)
EP (1) EP2665485B1 (OSRAM)
JP (1) JP2014504601A (OSRAM)
KR (1) KR20140071272A (OSRAM)
CN (1) CN103391786B (OSRAM)
AU (1) AU2012207301B2 (OSRAM)
CA (1) CA2823712A1 (OSRAM)
EA (1) EA028218B1 (OSRAM)
ES (1) ES2620404T3 (OSRAM)
IL (1) IL227207B (OSRAM)
MX (1) MX342020B (OSRAM)
SG (1) SG191992A1 (OSRAM)
WO (1) WO2012100010A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010347724B2 (en) * 2010-03-12 2016-06-23 Exxonmobil Upstream Research Company Dynamic grouping of domain objects via smart groups
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
JP6033433B2 (ja) * 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027629A1 (en) 1993-05-28 1994-12-08 Merck & Co., Inc. Method to control appetite and treat obesity
AU2001251245A1 (en) * 2000-04-05 2001-10-23 Genaissance Pharmaceuticals, Inc. Haplotypes of the apoa4 gene
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
WO2009116861A2 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103833712B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes

Also Published As

Publication number Publication date
US9051394B2 (en) 2015-06-09
EA201391063A1 (ru) 2013-12-30
CN103391786B (zh) 2016-06-22
MX342020B (es) 2016-09-08
EP2665485B1 (en) 2017-01-11
CN103391786A (zh) 2013-11-13
SG191992A1 (en) 2013-08-30
AU2012207301A8 (en) 2013-08-29
EP2665485A1 (en) 2013-11-27
KR20140071272A (ko) 2014-06-11
US9266941B2 (en) 2016-02-23
AU2012207301A1 (en) 2013-08-01
AU2012207301A2 (en) 2015-03-26
US20150252095A1 (en) 2015-09-10
WO2012100010A1 (en) 2012-07-26
MX2013008374A (es) 2013-12-06
CA2823712A1 (en) 2012-07-26
ES2620404T3 (es) 2017-06-28
US20140005107A1 (en) 2014-01-02
JP2014504601A (ja) 2014-02-24
EA028218B1 (ru) 2017-10-31
IL227207B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US11382956B2 (en) Amylin analogues
US9266941B2 (en) Apolipoprotein AIV as an antidiabetic peptide
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
AU2012366182B2 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
ES2871544T3 (es) Péptidos y métodos de uso de los mismos
KR102696075B1 (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
WO2017062693A1 (en) Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
ES2979305T3 (es) Composiciones y métodos para tratar enfermedades metabólicas
BR112014016734B1 (pt) Composições compreendendo um peptídeo e usos de composições e peptídeos no tratamento médico

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 27 , NO 29 , PAGE(S) 4349 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME UNIVERSITY OF CINCINNATI, APPLICATION NO. 2012207301, UNDER INID (54) CORRECT THE TITLE TO APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAR 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired